Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc.
private/Gazelle Parent, Inc.privateGalera Therapeutics and Obsidian Therapeutics merge in stock deal
Deal value
—
stock
Per-share offer
—
Premium
—
Days to close
—
Term fee
—
No structured deal economics extracted yet. Re-run the scanner or fall back to the source filing below.
Announced
Apr 24, 2026
Preliminary Proxy
—
Definitive Proxy
—
Record date
—
Shareholder vote
—
Expected close
—
No shareholder vote required for this transaction.
No regulatory or closing-conditions data extracted yet. The merger agreement Exhibit 10.1 contains this in the “Conditions to Closing” and “Regulatory Approvals” articles.
No closing-condition data extracted.
No competing-bidder, activist, or dissident-proxy signals in the database for this target.
Acquirer side· Gazelle Parent, Inc.
Legal
- · Asher Rubin
- · Istvan A. Hajdu
- · Kayla West
“With copies to: Asher Rubin, Esq. Istvan A. Hajdu, Esq. Kayla West, Esq. Sidley Austin LLP 787 7th Avenue New York, NY 10019 (212) 839-5300”
Target side· Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc.
Legal
- · William D. Collins
- · Gabriela Morales-Rivera
- · Tevia K. Pollard
“William D. Collins, Esq. Gabriela Morales-Rivera, Esq. Tevia K. Pollard, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 (617) 570-1000”
| Firm | Role | Side | Deals in DB | |
|---|---|---|---|---|
| Goodwin Procter LLP | Legal | Target | 7 | View deals → |
| Sidley Austin LLP | Legal | Acquirer | 3 | View deals → |
On April 14, 2026, Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. agreed to merge with Gazelle Parent, Inc. in a two-step merger transaction. The combined company will be renamed Obsidian Therapeutics, Inc. and trade on Nasdaq under ticker 'OBX'. Galera is also raising approximately $350 million in a concurrent Series C financing from certain investors.